Cipla, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong domestic demand, and said the U.S. freezing aid for some drug ...

Cipla share price will remain in focus after the United States Food and Drug Administration (USFDA) has classified the ...

Results: Pharmaceutical major Cipla on Tuesday reported a 49 per cent year-on-year (YoY) increase in its consolidated net profit for the December quarter (Q3 FY25) at Rs 1,574.6 crore, from Rs 1,068.5 ...

The shares of the third largest pharmaceutical firm Cipla rose 2.44 per cent at Rs 1,454.20 a piece on the BSE intraday after the company delivered a solid quarterly earnings ...

For the first nine months of the financial year, Cipla's EBITDA margin 26.9%, which is higher than the management guidance of 24.5% to 25.5% for the full year.

India's Cipla beats Q3 profit view as strong domestic ... joint venture with Nestle India and Nicotinell acquisition, the company said on Tuesday. India's Dr Reddy's Q2 profit drops on acquisition ...

During the year, the Company issued and allotted 2,16,469 equity shares of Rs. 2/- each to its employees under the Employee Stock Option Scheme 2013-A and the Cipla Employee StockAppreciation ...

The USFDA has conducted routine cGMP inspection at the facility in the period between November 7 through November 13, 2024.

KR Choksey recommended accumulate rating on Cipla with a target price of Rs 1598 in its research report dated January 31 2025.

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

Mumbai: Cipla has announced that the Company will invest approx. ZAR 900 million in equity share capital of Cipla Medpro ...

Mumbai: Cipla has announced that the United States Food and Drug Administration (USFDA) has classified the inspection at the Company’s manufacturing facility in Virgonagar, Bengaluru, India ...